Breast Cancer Clinical Trials in Richmond, Virginia

11 studies are recruiting for breast cancer in Richmond, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

   The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.

   Stage

   Not phased

   Ages

   18 and older

   Site

   VCU Massey Comprehensive Cancer Center, Richmond, Virginia

   Locations

   61 in total

   Run by

   Exact Sciences Corporation

   See if you can join NCT06401421 on ClinicalTrials.gov

2. Single FrAction Interstitial BreaSt BracHytherApy

   This phase 2, single arm prospective study has been designed to determine the safety of delivering accelerated partial breast irradiation (APBI) with a multicatheter interstitial implant in a single fraction over 1 day. This is a method of delivering radiation therapy directly into or close to a tu…

   Stage

   Phase 2

   Ages

   40 to 85

   Site

   Virginia Commonwealth University, Richmond, Virginia

   Run by

   Virginia Commonwealth University

   See if you can join NCT07654257 on ClinicalTrials.gov

3. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

   The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Bon Secours Cancer Institute at St. Mary's Hospital, Richmond, Virginia

   Locations

   433 in total

   Run by

   Pfizer

   See if you can join NCT07062965 on ClinicalTrials.gov

4. Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab

   The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health. The aims are to test the usability, feasibility, and acceptability o the intervention. Add…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Adult Outpatient Pavilion, Richmond, Virginia

   Locations

   3 in total

   Run by

   Virginia Commonwealth University

   See if you can join NCT07426913 on ClinicalTrials.gov

5. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

   The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Virginia Cancer Institute, Richmond, Virginia

   Locations

   567 in total

   Run by

   Stemline Therapeutics, Inc.

   See if you can join NCT06492616 on ClinicalTrials.gov

6. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

   This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

   Stage

   Phase 3

   Ages

   18 to 60

   Site

   Bon Secours Richmond Community Hospital, Richmond, Virginia

   Locations

   1261 in total

   Run by

   NRG Oncology

   See if you can join NCT05879926 on ClinicalTrials.gov

7. E-Mindfulness Approaches for Living After Breast Cancer

   NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants wi…

   Stage

   Phase 3

   Ages

   18 to 50

   Site

   Bon Secours Richmond Community Hospital, Richmond, Virginia

   Locations

   383 in total

   Run by

   NRG Oncology

   See if you can join NCT06748222 on ClinicalTrials.gov

8. Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

   Breast-conserving surgery followed by re-irradiation with partial breast irradiation (rPBI) has recently been found to be a safe alternative to mastectomy for women who have undergone prior whole breast radiation. By reducing the volume of tissue receiving radiation, rPBI has been associated with l…

   Stage

   Not phased

   Ages

   18 to 99

   Site

   Virgina Community University Massey Comprehensive Cancer Center, Richmond, Virginia

   Locations

   19 in total

   Run by

   University Health Network, Toronto

   See if you can join NCT05592938 on ClinicalTrials.gov

9. Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation

   This pilot study will evaluate the feasibility of at least twice daily use of azelaic acid in breast cancer patients undergoing radiation treatment.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Virginia Commonwealth University, Richmond, Virginia

   Run by

   Virginia Commonwealth University

   See if you can join NCT06966388 on ClinicalTrials.gov

10. PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients

    The purpose of this study is to provide prospective evidence in the US population of the frequency of skin discoloration and Sentinel Lymph Node detection rate in patients who have recevied Magtrace for Sentinel Lymph Node Biopsy (SLNB) and to evaluate the impact that skin discoloration has on pati…

    Stage

    Not phased

    Ages

    18 and older

    Site

    VCU Massey Comprehensive Cancer Center, Richmond, Virginia

    Locations

    2 in total

    Run by

    Endomagnetics Ltd.

    See if you can join NCT06610539 on ClinicalTrials.gov

11. ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy

    The purpose of this study is to compare any good and bad effects of giving radiation treatment for breast cancer in 3 treatments over about 2 days.

    Stage

    Phase 2

    Ages

    45 to 79

    Site

    Virginia Commonwealth University, Richmond, Virginia

    Run by

    Virginia Commonwealth University

    See if you can join NCT06185205 on ClinicalTrials.gov